TY - JOUR
T1 - Membrane bile acid receptor TGR5 predicts good prognosis in ampullary adenocarcinoma patients with hyperbilirubinemia
AU - Chen, Min Chan
AU - Chen, Yi Ling
AU - Wang, Tzu Wen
AU - Hsu, Hui Ping
AU - Lai, Ming Derg
N1 - Funding Information:
The present study was supported by grants from the National Science Council (grant NSC-102-B-2314-B-006-043), the Ministry of Science and Technology (grant MOST-104-B-2314-B-006-049), the National Cheng Kung University Hospital (to H.-P.H.), and the Chi Mei Medical Center (to M.-C.C.). The authors are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We were blessed with support from the late superintendent, Professor Pin-Wen Lin. Furthermore, we thank Mr. Chih-Yang Wang and Ms. Yu-Hsuan Hung for their support.
PY - 2016/10
Y1 - 2016/10
N2 - Bile acids are potential carcinogens in gastrointestinal cancer, and interact with nuclear and membrane receptors to initiate downstream signaling. The effect of TGR5 [also known as G protein-coupled bile acid receptor 1 (GPBAR1)] on cancer progression is dependent on the tissue where it is activated. In this report, the function of TGR5 expression in cancer was studied using a bioinformatic approach. TGR5 expression in ampullary adenocarcinoma and normal duodenum was compared by western blotting, reverse transcription polymerase chain reaction, and immunohistochemistry (IHC). High GPBAR1 gene expression was found to be an indicator of worse prognosis in gastric and breast cancer patients, and an indication of better prognosis in ovarian cancer patients. The level of GPBAR1 gene expression was higher in bile-acid exposed cancer than in other types of cancer, and was increased in well-differentiated ampullary adenocarcinoma. Negative, weak or mild expression of TGR5 was correlated with younger age, higher plasma level of total/direct bilirubin, higher plasma concentration of CA-125, advanced tumor stage and advanced AJCC TNM stage. The disease-specific survival rate was highest in ampullary adenocarcinoma patients with high TGR5 expression and high total bilirubin level. In summary, TGR5 functions as a tumor-suppressor in patients with ampullary adenocarcinoma and preoperative hyperbilirubinemia. Further study of the suppressive mechanism may provide a new therapeutic option for patients with ampullary adenocarcinoma.
AB - Bile acids are potential carcinogens in gastrointestinal cancer, and interact with nuclear and membrane receptors to initiate downstream signaling. The effect of TGR5 [also known as G protein-coupled bile acid receptor 1 (GPBAR1)] on cancer progression is dependent on the tissue where it is activated. In this report, the function of TGR5 expression in cancer was studied using a bioinformatic approach. TGR5 expression in ampullary adenocarcinoma and normal duodenum was compared by western blotting, reverse transcription polymerase chain reaction, and immunohistochemistry (IHC). High GPBAR1 gene expression was found to be an indicator of worse prognosis in gastric and breast cancer patients, and an indication of better prognosis in ovarian cancer patients. The level of GPBAR1 gene expression was higher in bile-acid exposed cancer than in other types of cancer, and was increased in well-differentiated ampullary adenocarcinoma. Negative, weak or mild expression of TGR5 was correlated with younger age, higher plasma level of total/direct bilirubin, higher plasma concentration of CA-125, advanced tumor stage and advanced AJCC TNM stage. The disease-specific survival rate was highest in ampullary adenocarcinoma patients with high TGR5 expression and high total bilirubin level. In summary, TGR5 functions as a tumor-suppressor in patients with ampullary adenocarcinoma and preoperative hyperbilirubinemia. Further study of the suppressive mechanism may provide a new therapeutic option for patients with ampullary adenocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=84984950719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984950719&partnerID=8YFLogxK
U2 - 10.3892/or.2016.5011
DO - 10.3892/or.2016.5011
M3 - Article
C2 - 27510297
AN - SCOPUS:84984950719
VL - 36
SP - 1997
EP - 2008
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 4
ER -